This review offers a contemporary analysis of the evolving landscape of pulmonary hypertension (PH) diagnosis and management. It synthesizes current evidence on disease mechanisms and therapeutic approaches, with particular emphasis on the pivotal changes introduced by the 2022 ESC/ERS guidelines. Central to this update is the revised hemodynamic definition of PH, now confirmed at a mean pulmonary arterial pressure >20 mm Hg at rest, and a stricter criterion for pulmonary arterial hypertension (PAH) requiring a pulmonary vascular resistance >2 Wood Units. The article navigates the refined diagnostic algorithm essential for accurately distinguishing between the five clinical PH groups. Furthermore, it elaborates on the modern, multi-parameter risk stratification strategy, a critical tool for prognostication and tailoring treatment intensity. The efficacy of established targeted drug classes–including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin pathway agents–is evaluated. The rationale for employing combination therapy and the indications for invasive procedures such as atrial septostomy and lung transplantation are also discussed. While a cure remains elusive, the systematic adoption of a personalized, risk-based treatment paradigm is demonstrated to markedly enhance functional capacity, quality of life, and long-term survival outcomes for patients.

1. Humbert, M., Kovacs, G., Hoeper, M. M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237.

2. Gall, H., Hoeper, M. M., Richter, M. J. et al. An epidemiological analysis of the burden of pulmonary arterial hypertension in Germany. Eur Respir J. 2017;50(2):1602409. doi:10.1183/13993003.02409–2016.

3. Hoeper, M. M., Humbert, M., Souza, R. et al. A glo bal view of pulmonary hypertension. Lancet Respir Med. 2016; 4(4):306–322. doi:10.1016/S2213–2600(15)00543–3.

4. Vachiéry, J. L., Tedford, R. J., Rosenkranz, S. et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. doi:10.1183/13993003.01897–2018.

5. Simonneau, G., Montani, D., Celermajer, D. S. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi:10.1183/13993003.01913–2018.

6. Hoeper, M. M., Pausch, C., Grünig, E. et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020;39(12):1435–1444. doi:10.1016/j.healun.2020.09.011.

7. Kim, N. H., Delcroix, M., Jais, X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1): 1801915. doi:10.1183/13993003.01915–2018.

8. Southgate, L., Machado, R. D., Gräf, S., Wilkinson, M. N. Molecular Genetic Framework for Pulmonary Arterial Hypertension. Nat Rev Cardiol. 2020;17(2):85–95. doi:10.1038/s41569–019–0242-x.

9. Montani, D., Savale, L., Natali, D., et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15): 1898–1907. doi:10.1093/eurheartj/ehq170.

10. Sobanski, V., Giovannelli, J., Lynch, B. M. et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol.2016;68(2): 484–493. doi:10.1002/art.39432.

11. Sitbon, O., Lascoux-Combe, C., Delfraissy, J. F. et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108–113. doi:10.1164/rccm.200704–541OC.

12. Krowka, M. J., Fallon, M. B., Kawut, S. M., et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016; 100(7):1440–1452. doi:10.1097/TP.0000000000001229.

13. D’Alto, M., Badagliacca, R., Budts, W. et al. Risk factors and outcomes in patients with pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2020;55(6):1902500. doi:10.1183/13993003.02500–2019.

14. Mandel, J., Mark, E. J., Hales, C. A. Pulmonary venoocclusive disease. Am J Respir Crit Care Med. 2000;162(5): 1964–1973. doi:10.1164/ajrccm.162.5.9912045.

15. Nathan, S. D., Barbera, J. A., Gaine, S. P. et al. Pulmonary hypertension in chronic lung disease and hypo xia. Eur Respir J. 2019;53(1):1801914. doi:10.1183/13993003.01914–2018.

16. Thenappan, T., Ormiston, M. L., Ryan, J. J., Archer, S. L. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. doi:10.1136/bmj.j5492.

17. Galiè, N., Channick, R. N., Frantz, R. P. et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889–2018.

18. Rudski, L. G., Lai, W. W., Afilalo, J. et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713. doi:10.1016/j.echo.2010.05.010.

19. Galiè, N., Barberà, J. A., Frost, A. E. et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834–844. doi:10.1056/NEJMoa1413687.

20. McLaughlin, V. V., Shah, S. J., Souza, R., Humbert, M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–1997. doi:10.1016/j.jacc.2015.03.540.